FX 322 / Astellas, Korro Bio - LARVOL DELTA

""Any" is not accurate. FX322 worked for this person in this story: https://t.co/48azbAyF9H" (@Eagledrag)

FX-322 in Adults With Acquired Sensorineural Hearing Loss (clinicaltrials.gov) - P2 | N=142 | Completed | Sponsor: Frequency Therapeutics | Active, not recruiting ➔ Completed

Trial completion • Otorhinolaryngology

FX-322 in Adults With Acquired Sensorineural Hearing Loss (clinicaltrials.gov) - P2 | N=142 | Active, not recruiting | Sponsor: Frequency Therapeutics | Recruiting ➔ Active, not recruiting | Trial primary completion date: Oct 2022 ➔ Jan 2023

Enrollment closed • Trial primary completion date • Otorhinolaryngology

FX-322 in Adults With Age-Related Sensorineural Hearing Loss (clinicaltrials.gov) - P1b | N=30 | Completed | Sponsor: Frequency Therapeutics | Active, not recruiting ➔ Completed

Trial completion • Otorhinolaryngology

FX-322 in Adults With Severe Sensorineural Hearing Loss (clinicaltrials.gov) - P1b | N=31 | Completed | Sponsor: Frequency Therapeutics | Active, not recruiting ➔ Completed

Trial completion • Otorhinolaryngology

FX-322 in Adults With Age-Related Sensorineural Hearing Loss (clinicaltrials.gov) - P1b; N=30; Active, not recruiting; Sponsor: Frequency Therapeutics; Completed ➔ Active, not recruiting; Trial completion date: Feb 2021 ➔ May 2022; Trial primary completion date: Oct 2020 ➔ Mar 2022

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Otorhinolaryngology

FX-322 in Adults With Acquired Sensorineural Hearing Loss (clinicaltrials.gov) - P2; N=124; Recruiting; Sponsor: Frequency Therapeutics

Clinical • New P2 trial • Otorhinolaryngology

FX-322 in Adults With Stable Sensorineural Hearing Loss (clinicaltrials.gov) - P2a; N=95; Completed; Sponsor: Frequency Therapeutics; Active, not recruiting ➔ Completed; Trial completion date: May 2021 ➔ Dec 2020

Clinical • Trial completion • Trial completion date • Otorhinolaryngology

FX-322 in Adults With Age-Related Sensorineural Hearing Loss (clinicaltrials.gov) - P1b; N=30; Completed; Sponsor: Frequency Therapeutics; Active, not recruiting ➔ Completed; Trial completion date: Jun 2021 ➔ Feb 2021; Trial primary completion date: Mar 2021 ➔ Oct 2020

Clinical • Trial completion • Trial completion date • Trial primary completion date • Otorhinolaryngology

FX-322 in Adults With Severe Sensorineural Hearing Loss (clinicaltrials.gov) - P1b; N=31; Active, not recruiting; Sponsor: Frequency Therapeutics; Recruiting ➔ Active, not recruiting

Enrollment closed • Otorhinolaryngology

FX-322 in Adults With Severe Sensorineural Hearing Loss (clinicaltrials.gov) - P1b; N=30; Recruiting; Sponsor: Frequency Therapeutics; Trial completion date: Jun 2021 ➔ Sep 2021

Clinical • Trial completion date • Otorhinolaryngology

Improved Speech Intelligibility in Subjects With Stable Sensorineural Hearing Loss Following Intratympanic Dosing of FX-322 in a Phase 1b Study. (PubMed, Otol Neurotol) - "Delivery of FX-322 to the extended high-frequency region of the cochlea is well tolerated and enhances speech recognition performance in multiple subjects with stable chronic hearing loss."

Clinical • Journal • P1 data • Otorhinolaryngology

FX-322 in Adults With Age-Related Sensorineural Hearing Loss (clinicaltrials.gov) - P1b; N=30; Active, not recruiting; Sponsor: Frequency Therapeutics; Recruiting ➔ Active, not recruiting; Trial primary completion date: Jun 2021 ➔ Mar 2021

Clinical • Enrollment closed • Trial primary completion date • Otorhinolaryngology

FX-322 in Adults With Severe Sensorineural Hearing Loss (clinicaltrials.gov) - P1b; N=30; Recruiting; Sponsor: Frequency Therapeutics

Clinical • New P1 trial • Otorhinolaryngology

FX-322 in Adults With Age-Related Sensorineural Hearing Loss (clinicaltrials.gov) - P1b; N=30; Recruiting; Sponsor: Frequency Therapeutics

Clinical • New P1 trial • Otorhinolaryngology

FX-322 in Adults With Stable Sensorineural Hearing Loss (clinicaltrials.gov) - P2a; N=95; Active, not recruiting; Sponsor: Frequency Therapeutics; Recruiting ➔ Active, not recruiting; Trial completion date: Sep 2020 ➔ May 2021

Clinical • Enrollment closed • Trial completion date • Otorhinolaryngology

"Frequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss https://t.co/GjGzjaDiRk" (@NewsFromBW)

P2a data • Otorhinolaryngology

"Is FX-322 testing delayed or still on track due to covid?" (@Capital54820510)